Rare Daily Staff
The contract manufacturer ChemGenes entered into a partnership with n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, to provide financial contribution and assistance in reducing manufacturing costs for its antisense oligonucleotides.
n-Lorem Foundation provides potentially life-saving treatments to patients who have diseases caused by extremely rare mutations (1 to 30 patients worldwide) for free, for life, by coupling advanced genomic diagnostics with antisense oligonucleotides (ASOs) medicines.
“Patients with diseases caused by ultra-rare mutations face unprecedented challenges, and we thank all of the organizations that have joined with us to try to help these patients in need,” said Stanley Crooke, founder, CEO and chairman of n-Lorem Foundation. “ChemGenes joins Ionis Pharmaceuticals, Biogen, Ultragenyx Pharmaceutical, Charles River Labs, Covance by Labcorp, and Korea Institute of Toxicology as industry partners supporting our efforts at n-Lorem. With more support from additional collaborators, we can improve the lives of more patients in need.”
Photo: Stanley Crooke, founder, CEO and chairman of n-Lorem Foundation
Stay Connected
Sign up for updates straight to your inbox.